Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.
about
Tracking antigen-specific T-cells during clinical tolerance induction in humansImmune regulation of human herpesviruses and its implications for human transplantationSimian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans.Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka.IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors.Direct ex-vivo evaluation of pneumococcal specific T-cells in healthy adultsSafety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled studyIncreases in human papillomavirus detection during early HIV infection among women in Zimbabwe.A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.Simian varicella virus infection of Chinese rhesus macaques produces ganglionic infection in the absence of rash.Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) VaccinationVaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.Immunogenicity of varicella zoster virus glycoprotein E DNA vaccineT-cell immunity to human alphaherpesviruses.Efficacy of varicella (VZV) vaccination: an update for the clinician.Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaquesInfluence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.The herpes zoster subunit vaccine.Herpes zoster and the search for an effective vaccine.The life cycle of a T cell after vaccination - where does immune ageing strike?Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses.Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits.Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.Varicella Virus Vaccination in the United States.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses.Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity
P2860
Q24320083-65F10416-17B1-4C8C-8FD3-F3725F1EDCB3Q26992146-A0F3C038-B18A-4617-BC45-5A636DAFA2F9Q30884283-35024C75-10E8-4D1F-B281-F08B5037DF85Q33386017-E7F1C90C-046F-4299-B9C4-D7A2483473C0Q33723698-18B4FAA2-9479-4E05-A5AB-74D9F3BACF46Q33826872-B2A0B634-3845-452E-BD5B-F982C1865ADAQ34062231-9223871D-4732-4D5B-A5AE-EC1EE2ADF526Q34446365-F5FE1C99-7041-471C-B340-831CC1E8E482Q34743282-D599D9F4-F7BA-4B49-8386-A535ECDAF27DQ35081168-695A466B-B5C7-4C85-809D-788378115BC8Q35886301-6DFB135A-A7E1-4500-B6A7-B6072B234868Q36006384-7473C369-9626-41CE-BDA0-1CAB7A89F241Q36024466-BF0E45D9-32AF-47FF-87A6-748DB0B877F9Q36237622-768E5F2E-37A2-4FAB-BEE5-FF891B804DBFQ36276185-730ED7C1-4A9E-4B3E-A873-691464E6FF35Q36825131-1F59974F-425B-4320-BF91-E5A0452D0C47Q37107189-3DC0C422-1B84-4728-9268-8B462136CF8DQ37158220-7A62EA2D-9F10-446B-B9D1-4623A446BC79Q37252780-0EC14609-679B-4ED7-9B97-619BB611E2E0Q37643309-F74E3AE6-77A7-4B67-BD5B-CBF1AE9B50EEQ38728931-91062E34-47FF-4EE1-89B1-462F22AEF7B2Q38831062-A2D89427-EA02-44BB-B301-200994B903CBQ38871207-AC72C5EF-27CB-4840-A6F1-86C8AAC5FE21Q39370192-845AAB93-7667-41FA-9439-E971098B393FQ40162587-5CAAD336-DDCB-4A62-B6A0-74AD75EE5444Q40757793-0276DAC9-9579-41D7-87B3-913A97C240DBQ40876878-AB9BB4DF-CBF4-4054-A258-AE16A068C497Q40995378-0DB59DA4-6C43-4F3F-B8A0-035206AE382BQ42279944-110171C1-5B8C-4567-925D-52E5141BB14CQ45324301-9C781935-E11D-4FB1-96BF-801CABFB3F0FQ46892547-17BC5F7B-C431-42CE-9254-349042EBEF0DQ50105407-D483233D-A22A-4914-9DB3-3F28B5CFF048Q51029588-0A5CC0AC-4E81-4BC5-9A28-DDB7C78984BEQ58584452-BCF61D2F-3BD6-4FAD-A98E-6F6A176E5251
P2860
Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Varicella zoster virus glycopr ...... gens in healthy immune donors.
@en
Varicella zoster virus glycopr ...... gens in healthy immune donors.
@nl
type
label
Varicella zoster virus glycopr ...... gens in healthy immune donors.
@en
Varicella zoster virus glycopr ...... gens in healthy immune donors.
@nl
prefLabel
Varicella zoster virus glycopr ...... gens in healthy immune donors.
@en
Varicella zoster virus glycopr ...... gens in healthy immune donors.
@nl
P2093
P2860
P1476
Varicella zoster virus glycopr ...... igens in healthy immune donors
@en
P2093
P2860
P304
P356
10.1111/J.1365-2249.2008.03633.X
P577
2008-03-20T00:00:00Z